Real-time Estimate Cboe BZX 01:20:26 2024-04-26 pm EDT 5-day change 1st Jan Change
15.83 USD +2.26% Intraday chart for ZimVie Inc. +2.40% -10.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
H.I.G. Capital, LLC completed the acquisition of Zimmer Biomet Spine, Inc. from ZimVie Inc.. CI
ZimVie Inc.(NasdaqGS:ZIMV) added to S&P Healthcare Equipment Select Industry Index CI
Barclays Adjusts Price Target on ZimVie to $16 From $13, Maintains Underweight Rating MT
Transcript : ZimVie Inc., Q4 2023 Earnings Call, Feb 28, 2024
ZimVie Inc. Provides Earnings Guidance for First Quarter and Raises Earnings Guidance for the Full Year 2024 CI
ZimVie Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
(ZIMV) ZIMVIE Expects Q1 Revenue Range $115M - $118M MT
Earnings Flash (ZIMV) ZIMVIE Reports Q4 Revenue $113.1M MT
Earnings Flash (ZIMV) ZIMVIE Reports Q4 EPS $0.11, vs. Street Est of $0.13 MT
ZimVie Inc. Announces Launch of Next-Generation TSX®? Implant in Japan CI
Top Midday Gainers MT
ZimVie to Sell Spine Business to H.I.G. Capital for $375 Million; Shares Rise MT
H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. for approximately $380 million. CI
ZimVie Inc. Announces Compatibility Between Its Vital Spinal Fixation System and Brainlab Spine & Trauma Navigation CI
Needham Starts ZimVie With Hold Rating MT
Top Premarket Decliners MT
Transcript : ZimVie Inc., Q3 2023 Earnings Call, Nov 01, 2023
(ZIMV) ZIMVIE Forecasts Fiscal Year 2023 EPS Range $0.60 - $0.70 MT
Earnings Flash (ZIMV) ZIMVIE Reports Q3 Revenue $202.9M, vs. Street Est of $196M MT
Earnings Flash (ZIMV) ZIMVIE Posts Q3 EPS $0.08, vs. Street Est of $-0.02 MT
Zimvie Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023 CI
ZimVie Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ZimVie Inc. Announces First U.S. Surgery with the 4.5mm Mobi-C(R) Cervical Disc CI
ZimVie Inc. Announces the Launch of Azure Multi-Platform Product Solutions CI
ZimVie Inc. Announces the Recent Launch of Biotivity A/C Plus Membrane CI
Chart ZimVie Inc.
More charts
ZimVie Inc. is a global life sciences company in the dental market. The Company develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. The Company works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including dental implants, biomaterials, and digital workflow solutions. In the dental segment, its core services include designing, manufacturing and distributing dental implant systems. The key products in its dental implant systems portfolio include the T3 Implant, Tapered Screw-Vent Implant System, Trabecular Metal Dental Implant, BellaTek Encode Impression System, and Puros Allograft Particulate. The Company markets its products in about 70 countries in North America, Europe, Latin America and Asia.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
15.48 USD
Average target price
16 USD
Spread / Average Target
+3.36%
Consensus
  1. Stock Market
  2. Equities
  3. ZIMV Stock
  4. News ZimVie Inc.
  5. ZimVie Says Anthem Issues Positive Policy Decision for Scoliosis Treatment